Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay

Wonil Chae, Paul Kim, Beom Jeung Hwang, Baik Lin Seong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Seasonal and pandemic influenza infections remain a serious public health concern. Many health authorities recommend annual vaccination as the most effective way to control influenza infection. Accordingly, regulatory guidelines ask vaccine manufacturers to determine vaccine potency at the time of release and throughout shelf-life to ensure vaccine quality. The potency of inactivated influenza vaccine is related to the quantity of hemagglutinin (HA). Since 1970s, single radial immunodiffusion (SRID) assay has been standardly used for the quantitation of HA in influenza vaccine. However, SRID is labor-intensive, inaccurate, and requires standard reference reagents that should be updated annually. Therefore, there have been extensive efforts to develop alternative potency assays. In this study, we developed and tested a new HA quantitative enzyme-linked immunosorbent assay (ELISA) using a universal monoclonal antibody that can bind to HAs from various subtypes in group 1 influenza A virus (IAV). We analyzed the conserved stalk domain of HA via a library approach to design a consensus HA antigen for group 1 IAV. The antigens were expressed as a soluble form in E. coli and were purified by Ni-affinity chromatography. When tested with variety of HAs from IAVs or influenza B viruses (IBVs), the mAbs exhibited specific binding to group 1 HAs, with potential exception to H9 subtype. Among various conditions of pH, urea, and reducing agents, pretreatment of HA at low pH exposing the conserved stalk domain was crucially important for optimal ELISA performance. Calibration curves for various HAs were generated to determine accuracy, specificity, sensitivity, and linear dynamic range. The ELISA method shows high sensitivity and accuracy compared with the SRID assay. The HA group specific universal mAbs against the consensus stalk domain of HA are conducive to establishing an ELISA-based standard procedure for the quantitation of HA antigens for annual vaccination against influenza infection.

Original languageEnglish
Pages (from-to)1457-1466
Number of pages10
JournalVaccine
Volume37
Issue number11
DOIs
Publication statusPublished - 2019 Mar 7

Fingerprint

Hemagglutinins
hemagglutinins
influenza
Human Influenza
monoclonal antibodies
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies
enzyme-linked immunosorbent assay
vaccines
Immunodiffusion
Influenza Vaccines
Influenza A virus
antigens
Antigens
Vaccination
assays
Vaccines
Influenza B virus
vaccination
Vaccine Potency

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Chae, Wonil ; Kim, Paul ; Hwang, Beom Jeung ; Seong, Baik Lin. / Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay. In: Vaccine. 2019 ; Vol. 37, No. 11. pp. 1457-1466.
@article{a415b85ab4d648958d9d081d5e52866b,
title = "Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay",
abstract = "Seasonal and pandemic influenza infections remain a serious public health concern. Many health authorities recommend annual vaccination as the most effective way to control influenza infection. Accordingly, regulatory guidelines ask vaccine manufacturers to determine vaccine potency at the time of release and throughout shelf-life to ensure vaccine quality. The potency of inactivated influenza vaccine is related to the quantity of hemagglutinin (HA). Since 1970s, single radial immunodiffusion (SRID) assay has been standardly used for the quantitation of HA in influenza vaccine. However, SRID is labor-intensive, inaccurate, and requires standard reference reagents that should be updated annually. Therefore, there have been extensive efforts to develop alternative potency assays. In this study, we developed and tested a new HA quantitative enzyme-linked immunosorbent assay (ELISA) using a universal monoclonal antibody that can bind to HAs from various subtypes in group 1 influenza A virus (IAV). We analyzed the conserved stalk domain of HA via a library approach to design a consensus HA antigen for group 1 IAV. The antigens were expressed as a soluble form in E. coli and were purified by Ni-affinity chromatography. When tested with variety of HAs from IAVs or influenza B viruses (IBVs), the mAbs exhibited specific binding to group 1 HAs, with potential exception to H9 subtype. Among various conditions of pH, urea, and reducing agents, pretreatment of HA at low pH exposing the conserved stalk domain was crucially important for optimal ELISA performance. Calibration curves for various HAs were generated to determine accuracy, specificity, sensitivity, and linear dynamic range. The ELISA method shows high sensitivity and accuracy compared with the SRID assay. The HA group specific universal mAbs against the consensus stalk domain of HA are conducive to establishing an ELISA-based standard procedure for the quantitation of HA antigens for annual vaccination against influenza infection.",
author = "Wonil Chae and Paul Kim and Hwang, {Beom Jeung} and Seong, {Baik Lin}",
year = "2019",
month = "3",
day = "7",
doi = "10.1016/j.vaccine.2019.01.068",
language = "English",
volume = "37",
pages = "1457--1466",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "11",

}

Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay. / Chae, Wonil; Kim, Paul; Hwang, Beom Jeung; Seong, Baik Lin.

In: Vaccine, Vol. 37, No. 11, 07.03.2019, p. 1457-1466.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay

AU - Chae, Wonil

AU - Kim, Paul

AU - Hwang, Beom Jeung

AU - Seong, Baik Lin

PY - 2019/3/7

Y1 - 2019/3/7

N2 - Seasonal and pandemic influenza infections remain a serious public health concern. Many health authorities recommend annual vaccination as the most effective way to control influenza infection. Accordingly, regulatory guidelines ask vaccine manufacturers to determine vaccine potency at the time of release and throughout shelf-life to ensure vaccine quality. The potency of inactivated influenza vaccine is related to the quantity of hemagglutinin (HA). Since 1970s, single radial immunodiffusion (SRID) assay has been standardly used for the quantitation of HA in influenza vaccine. However, SRID is labor-intensive, inaccurate, and requires standard reference reagents that should be updated annually. Therefore, there have been extensive efforts to develop alternative potency assays. In this study, we developed and tested a new HA quantitative enzyme-linked immunosorbent assay (ELISA) using a universal monoclonal antibody that can bind to HAs from various subtypes in group 1 influenza A virus (IAV). We analyzed the conserved stalk domain of HA via a library approach to design a consensus HA antigen for group 1 IAV. The antigens were expressed as a soluble form in E. coli and were purified by Ni-affinity chromatography. When tested with variety of HAs from IAVs or influenza B viruses (IBVs), the mAbs exhibited specific binding to group 1 HAs, with potential exception to H9 subtype. Among various conditions of pH, urea, and reducing agents, pretreatment of HA at low pH exposing the conserved stalk domain was crucially important for optimal ELISA performance. Calibration curves for various HAs were generated to determine accuracy, specificity, sensitivity, and linear dynamic range. The ELISA method shows high sensitivity and accuracy compared with the SRID assay. The HA group specific universal mAbs against the consensus stalk domain of HA are conducive to establishing an ELISA-based standard procedure for the quantitation of HA antigens for annual vaccination against influenza infection.

AB - Seasonal and pandemic influenza infections remain a serious public health concern. Many health authorities recommend annual vaccination as the most effective way to control influenza infection. Accordingly, regulatory guidelines ask vaccine manufacturers to determine vaccine potency at the time of release and throughout shelf-life to ensure vaccine quality. The potency of inactivated influenza vaccine is related to the quantity of hemagglutinin (HA). Since 1970s, single radial immunodiffusion (SRID) assay has been standardly used for the quantitation of HA in influenza vaccine. However, SRID is labor-intensive, inaccurate, and requires standard reference reagents that should be updated annually. Therefore, there have been extensive efforts to develop alternative potency assays. In this study, we developed and tested a new HA quantitative enzyme-linked immunosorbent assay (ELISA) using a universal monoclonal antibody that can bind to HAs from various subtypes in group 1 influenza A virus (IAV). We analyzed the conserved stalk domain of HA via a library approach to design a consensus HA antigen for group 1 IAV. The antigens were expressed as a soluble form in E. coli and were purified by Ni-affinity chromatography. When tested with variety of HAs from IAVs or influenza B viruses (IBVs), the mAbs exhibited specific binding to group 1 HAs, with potential exception to H9 subtype. Among various conditions of pH, urea, and reducing agents, pretreatment of HA at low pH exposing the conserved stalk domain was crucially important for optimal ELISA performance. Calibration curves for various HAs were generated to determine accuracy, specificity, sensitivity, and linear dynamic range. The ELISA method shows high sensitivity and accuracy compared with the SRID assay. The HA group specific universal mAbs against the consensus stalk domain of HA are conducive to establishing an ELISA-based standard procedure for the quantitation of HA antigens for annual vaccination against influenza infection.

UR - http://www.scopus.com/inward/record.url?scp=85061247417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061247417&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.01.068

DO - 10.1016/j.vaccine.2019.01.068

M3 - Article

C2 - 30765169

AN - SCOPUS:85061247417

VL - 37

SP - 1457

EP - 1466

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 11

ER -